FlowCardia, acquired by C. R. Bard in 2010, developed and marketed products for the treatment of chronic total occlusions (CTOs) of coronary and peripheral arteries. Utilizing a technology known as high-frequency mechanical recanalization, the company developed the CROSSER™ System to safely and quickly break up CTOs allowing subsequent stent placement or balloon angioplasty and avoiding the trauma of cardiac surgery.